ERBB3, a member of the epidermal growth factor receptor (EGFR) family, is unique in that its
tyrosine kinase domain is functionally defective. It is activated by neuregulins, by other …

Over the last several years major advances in sensitive high throughput technologies have
been made in the fields of genomics and proteomics. The hunt for diagnostic and prognostic …

Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR)
are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of …

Purpose Patients with non–small-cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR)–activating mutations have excellent response to EGFR tyrosine kinase …

Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their
mechanism of activation and effects on drug binding, we studied the kinetics of the L858R …

Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Purpose: Non–small cell lung cancers carrying activating mutations in the gene for the
epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine …

We show that two commonly occurring epidermal growth factor receptor (EGFR) somatic
mutations, L858R and an in-frame deletion mutant, Del (746-750), exhibit distinct enzymatic …

The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR)
pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the …

The androgen receptor (AR) mediates the effects of male sex steroids. There are major sex
differences in lung development and pathologies, including lung cancer. In this report, we …